Bone-targeting macromolecular therapeutics

Wang, Dong; Miller, Scott C.; Kopečková, Pavla; Kopeček, Jindřich

doi:10.1016/j.addr.2004.12.011

Cited by 180 publications

(136 citation statements)

References 173 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…The small size, customized surface, improved solubility, and multi-functionality of NPs continue to open many doors and create new biomedical applications (Singh & Lillard 2009). The size of the NPs should be less the 100 nm in diameter for delivering the drugs to the bone (Wang et al, 2005). The smaller size NPs can be developed easily with polymers using simple and economical methods.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…21,22 As a bone-targeting drug agent, TC offers the advantages of being relatively nontoxic compared to bisphosphonates. 20,23,24 In addition, the biological activity of pharmaceutical TC is less susceptible to physicochemical factors and physiological environments compared with bone-targeting biological agents such as acidic oligopeptides and aptamers. 20, 25 Wang et al 26 reported the development of nanoparticles (NPs) that target bone tissue by poly(lactic-co-glycolic acid) copolymers and TC-based bonetargeting moieties and found that the NPs loaded with SV could improve the curative effects of SV on the recovery of bone mineral density in vivo.…”

Section: Introductionmentioning

confidence: 99%

Study of a new bone-targeting titanium implant–bone interface

Liu¹,

Zhang²,

Li³

et al. 2016

IJN

View full text Add to dashboard Cite

“…HAp also has been investigated as a material for drug delivery systems due to its chemical similarity to the inorganic phase of bones as well as its ability to adsorb and release several molecules of biological interest [4][5][6][7][8] .…”

Section: Introductionmentioning

confidence: 99%

Effect of Tryptophan Residues on Adsorption of a Cationic Arginine Rich Polypeptide by Hydroxyapatite Nanoparticles and Following Translocation of the Polypeptide Through a Lipid Vesicle Membrane

Ueno

Shimabayashi

Saito

2011

Phosphorus Research Bulletin

View full text Add to dashboard Cite

Hydroxyapatite (abbreviated to HAp), in general, adsorbs a polypeptide, resulting in a HAp-peptide complex. In the present paper the Hap was of a nanosized particle and peptide was poly-L-arginine (abbreviated to poly(Arg)) or copoly(L-arginine/ L-tryptophan = 4:1) (abbreviated to poly(Arg,Trp)). Physicochemical properties of these complexes were quite different with each other due mainly to the presence or absence of tryptophan residues on the polymer chain. The adsorption amount of poly(Arg,Trp) on HAp was much larger than that of poly(Arg). Zeta potential of the HAp-poly(Arg,Trp) complex was far lower than that of the HAp-poly(Arg) complex. Considering these facts, it was concluded that hydrophobic interaction between Trp residues of poly(Arg,Trp) induced an adsorption bilayer on HAp, while poly(Arg) simply formed an adsorption monolayer through electrostatic interaction. On the other hand, structural flexibility of a copolymer and its translocation through a lipid membrane were lower and slower in poly(Arg,Trp) than in poly(Arg).

show abstract

Bone-targeting macromolecular therapeutics

Cited by 180 publications

References 173 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Study of a new bone-targeting titanium implant–bone interface

Effect of Tryptophan Residues on Adsorption of a Cationic Arginine Rich Polypeptide by Hydroxyapatite Nanoparticles and Following Translocation of the Polypeptide Through a Lipid Vesicle Membrane

Contact Info

Product

Resources

About

Bone-targeting macromolecular therapeutics

Cited by 180 publications

References 173 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Study of a new bone-targeting titanium implant&ndash;bone interface

Effect of Tryptophan Residues on Adsorption of a Cationic Arginine Rich Polypeptide by Hydroxyapatite Nanoparticles and Following Translocation of the Polypeptide Through a Lipid Vesicle Membrane

Contact Info

Product

Resources

About

Study of a new bone-targeting titanium implant–bone interface